Merck Inc. known as MSD outside of the United States and Canada, announced that Health Canada has approved a new indication for Prevymis (letermovir) for the prophylaxis of cytomegalovirus (CMV) disease in adult kidney transplant recipients at high risk (Donor CMV-seropositive/Recipient CMV-seronegative [D+/R-]).
Merck Inc. known as MSD outside of the United States and Canada, announced the FDA has approved a new indication for Prevymis (letermovir) for prophylaxis of cytomegalovirus (CMV) disease in adult kidney transplant recipients at high risk (Donor seropositive/Recipient CMV-seronegative [D+/R-]) following a priority review
The EU has approved Prevymis (letermovir), from Merck Sharp & Dohme.
Merck & Co., Inc. has announced that the FDA has approved Prevymis (letermovir).
Merck & Co., Inc. announced that the FDA has approved Prevymis (letermovir) once-daily tablets for oral use and injection for...
Merck Inc., announced the presentation of findings from a Phase III clinical trial that assessed safety and efficacy of Prevymis (letermovir) compared to valganciclovir for cytomegalovirus (CMV) prophylaxis in 601 adult kidney transplant recipients at high risk for CMV disease (D+/R-).
Merck Inc., announced the presentation of findings from a systematic literature review and meta-analysis of data from real-world observational studies of Prevymis (letermovir) for primary prophylaxis (prevention) of cytomegalovirus (CMV) infection and disease in patients undergoing allogeneic hematopoietic cell transplantation (alloHCT) who were CMV-seropositive.
Merck Inc., known as MSD outside of the United States and Canada, announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended the approval of Prevymis (letermovir) for prophylaxis of cytomegalovirus (CMV) disease in adult kidney transplant recipients at high risk (Donor CMV-seropositive/Recipient CMV-seronegative [D+/R-]).